Investigating Hereditary Risk In Thoracic Cancers (INHERIT) (NCT05587439)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Cohort 1: individuals with or with high risk of carrying an EGFR T790M or other EGFR germline variant identified in blood or saliva, including via somatic single or multi-gene panel testing (MGPT). This includes both probands and family members.
2. Participants with variants of uncertain significance may be eligible at the PI's discretion
3. Cohort 2: individuals with or with high risk of carrying non-EGFR germline variants suggestive of a potential inherited lung cancer risk, identified in blood or saliva, including via somatic single or multi-gene panel testing (MGPT). This includes both probands and family members.
4. Participants with variants of uncertain significance may be eligible at the PI's discretion
5. Cohort 3: individuals with lung cancer who are not known to carry a pathogenic or likely pathogenic variant, and with one of the following:
6. first-degree relative with lung cancer
7. multi-generational family history of lung cancer
8. personal history of multiple primary lung cancers or other neoplasms
9. multifocal lung cancer This includes both probands and their families.
10. For each cohort, the following applies:
11. May include blood relatives of individuals with the aforementioned variants or family history, who may be presumed obligate carriers or healthy controls
12. Deceased patients may be included in the study. Pathology specimens and public records, such as death certificates, may be used to confirm information. If medical records and/or pathology specimens are needed, consent will be obtained from the descendant's next-of-kin. Next-of-kin refers to the following hierarchy of relatives: spouse, offspring, parents, and siblings. (Any further use of "next-of-kin" in this protocol refers to this hierarchy).

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (2 Sites)

• Brigham and Women's Hospital — Boston, Massachusetts
• Dana-Farber Cancer Institute — Boston, Massachusetts

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.